| pubmed-article:17507306 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17507306 | lifeskim:mentions | umls-concept:C0019682 | lld:lifeskim |
| pubmed-article:17507306 | lifeskim:mentions | umls-concept:C0019699 | lld:lifeskim |
| pubmed-article:17507306 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17507306 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:17507306 | lifeskim:mentions | umls-concept:C0376298 | lld:lifeskim |
| pubmed-article:17507306 | lifeskim:mentions | umls-concept:C1556085 | lld:lifeskim |
| pubmed-article:17507306 | lifeskim:mentions | umls-concept:C0537439 | lld:lifeskim |
| pubmed-article:17507306 | lifeskim:mentions | umls-concept:C0034866 | lld:lifeskim |
| pubmed-article:17507306 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:17507306 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:17507306 | pubmed:dateCreated | 2007-5-17 | lld:pubmed |
| pubmed-article:17507306 | pubmed:abstractText | The EU approval of enfuvirtide (Fuzeon) was granted in May 2003 on the basis of the 48-week data from the TORO 1 and TORO 2 studies. Enfuvirtide is licensed for use in pretreated HIV patients experienced with three classes of drugs who exhibited treatment failure or who have shown intolerance to previous antiretroviral treatment regimens. Recent studies with the new protease inhibitors tipranavir and darunavir (RESIST and POWER studies) showed that a high proportion of heavily pretreated HIV patients achieve a viral load reduction to below the limit of detection when treated with enfuvirtide plus one of these new ritonavir-boosted protease inhibitors and an optimised background treatment regimen. The International AIDS Society (IAS-USA Panel) has recently updated its treatment guidelines in view of these new data and recommends the use of an antiretroviral treatment regimen containing at least two active drugs, one of which that has a new mechanism of action, for HIV patients who have been heavily pretreated. A new treatment goal has also emerged for heavily pretreated patients with advanced HIV disease: reduction of the viral load to below the detection limit of 50 copies/ml. The IAS concluded that the likelihood of achieving this treatment goal is higher when enfuvirtide is selected as one of the two active drugs. | lld:pubmed |
| pubmed-article:17507306 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17507306 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17507306 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17507306 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17507306 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17507306 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17507306 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17507306 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17507306 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17507306 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:17507306 | pubmed:issn | 0949-2321 | lld:pubmed |
| pubmed-article:17507306 | pubmed:author | pubmed-author:StollMM | lld:pubmed |
| pubmed-article:17507306 | pubmed:author | pubmed-author:JaegerHH | lld:pubmed |
| pubmed-article:17507306 | pubmed:author | pubmed-author:MayoDD | lld:pubmed |
| pubmed-article:17507306 | pubmed:author | pubmed-author:StaszewskiSS | lld:pubmed |
| pubmed-article:17507306 | pubmed:author | pubmed-author:MollAA | lld:pubmed |
| pubmed-article:17507306 | pubmed:author | pubmed-author:SalzbergerBB | lld:pubmed |
| pubmed-article:17507306 | pubmed:author | pubmed-author:van LunzenJJ | lld:pubmed |
| pubmed-article:17507306 | pubmed:author | pubmed-author:StellbrinkH... | lld:pubmed |
| pubmed-article:17507306 | pubmed:author | pubmed-author:RockstrohJJ | lld:pubmed |
| pubmed-article:17507306 | pubmed:author | pubmed-author:PlettenbergAA | lld:pubmed |
| pubmed-article:17507306 | pubmed:author | pubmed-author:KnechtenHH | lld:pubmed |
| pubmed-article:17507306 | pubmed:author | pubmed-author:MaussSS | lld:pubmed |
| pubmed-article:17507306 | pubmed:author | pubmed-author:GutePP | lld:pubmed |
| pubmed-article:17507306 | pubmed:author | pubmed-author:DäumerMM | lld:pubmed |
| pubmed-article:17507306 | pubmed:author | pubmed-author:SturmerMM | lld:pubmed |
| pubmed-article:17507306 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17507306 | pubmed:day | 26 | lld:pubmed |
| pubmed-article:17507306 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:17507306 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17507306 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17507306 | pubmed:pagination | 93-102 | lld:pubmed |
| pubmed-article:17507306 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:17507306 | pubmed:meshHeading | pubmed-meshheading:17507306... | lld:pubmed |
| pubmed-article:17507306 | pubmed:meshHeading | pubmed-meshheading:17507306... | lld:pubmed |
| pubmed-article:17507306 | pubmed:meshHeading | pubmed-meshheading:17507306... | lld:pubmed |
| pubmed-article:17507306 | pubmed:meshHeading | pubmed-meshheading:17507306... | lld:pubmed |
| pubmed-article:17507306 | pubmed:meshHeading | pubmed-meshheading:17507306... | lld:pubmed |
| pubmed-article:17507306 | pubmed:meshHeading | pubmed-meshheading:17507306... | lld:pubmed |
| pubmed-article:17507306 | pubmed:meshHeading | pubmed-meshheading:17507306... | lld:pubmed |
| pubmed-article:17507306 | pubmed:meshHeading | pubmed-meshheading:17507306... | lld:pubmed |
| pubmed-article:17507306 | pubmed:meshHeading | pubmed-meshheading:17507306... | lld:pubmed |
| pubmed-article:17507306 | pubmed:meshHeading | pubmed-meshheading:17507306... | lld:pubmed |
| pubmed-article:17507306 | pubmed:meshHeading | pubmed-meshheading:17507306... | lld:pubmed |
| pubmed-article:17507306 | pubmed:meshHeading | pubmed-meshheading:17507306... | lld:pubmed |
| pubmed-article:17507306 | pubmed:meshHeading | pubmed-meshheading:17507306... | lld:pubmed |
| pubmed-article:17507306 | pubmed:meshHeading | pubmed-meshheading:17507306... | lld:pubmed |
| pubmed-article:17507306 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17507306 | pubmed:articleTitle | Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients. | lld:pubmed |
| pubmed-article:17507306 | pubmed:affiliation | Klinik I fuer Innere Medizin, Universitaetsklinik Regensburg, 93042 Regensburg, Germany. bernd.salzberger@klinik.uni-regensburg.de | lld:pubmed |
| pubmed-article:17507306 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17507306 | pubmed:publicationType | Practice Guideline | lld:pubmed |
